Lumexa (LMRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 11 | $124 | $116.16 | -$7.84 | -6.32% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 61,606 | $694,915.68 | $661,944.15 | -$32,971.53 | -4.74% |
| KM Kristin Mariani Janus Henderson Group PLC | 1.99M | $36.86M | $21.48M | -$15.38M | -41.73% |
| CD Charlie Durham Sterling Capital Management LLC | 27,801 | $311,692.21 | $293,578.56 | -$18,113.65 | -5.81% |
Point72 Asset Management LP Point72 Asset Management LP | 280,963 | $3.87M | $3.03M | -$840,752.1 | -21.73% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Caitlin Zulla CEO | NASDAQ (NGS) Exchange | 550249106 CUSIP |
| US Country | 5,000 Employees | - Last Dividend | - Last Split | - IPO Date |